Metal thiosemicarbazonates as dual mR2 RNR and colchicine-site tubulin inhibitors: from biochemical inhibition to mitotic arrest in MCF-7 breast cancer cells
Cancer cells exploit multiple proliferation pathways, making single-target therapies vulnerable to resistance. Here, a thiosemicarbazone-based strategy is introduced for striking two validated oncotargets, the R2 subunit of ribonucleotide reductase (RNR) and the colchicine site of tubulin, with one agent. Guided by mol...